<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39997">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01657123</url>
  </required_header>
  <id_info>
    <org_study_id>33088</org_study_id>
    <nct_id>NCT01657123</nct_id>
  </id_info>
  <brief_title>Exercise Capacity and Recovery in Addison's Disease</brief_title>
  <official_title>Effect of Hydrocortisone Stress Dose on Exercise Capacity and Post-exercise Recovery in Patients With Addison's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <authority>The Netherlands: Julius Clinical Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exposure to stress alters the activity of the adrenomedullary, adrenocortical and
      sympathetic nervous system, depending on the type and intensity of the stressor. Physical
      exercise represents a stress condition influencing many systems in the body. Given a
      workload of at least 70-85% of Vo2max, exercise is a potent stimulus of the
      hypothalamic-pituitary-adrenal (HPA)-axis. The increased endogenous cortisol secretion
      results in important metabolic and cardiovascular effects to maintain cellular and organ
      homeostasis. Patients with Addison's disease are not able to meet the increased demand of
      adrenal steroids in case of physical exercise, which may result in an impaired exercise
      capacity and a prolonged post-exercise recovery. We hypothesize that a hydrocortisone stress
      dose increases exercise capacity and improves post-exercise recovery in patients with
      Addison's disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>exercise capacity</measure>
    <time_frame>140 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>power in Watt and duration in minutes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Addison's Disease</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>hydrocortisone stress dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ergometry</intervention_name>
    <description>ergometry measurements</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ergometry</intervention_name>
    <description>Ergometry measurements</description>
    <arm_group_label>hydrocortisone stress dosage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Addison's disease

          -  18-50 years

          -  stable glucocortiocid replacement therapy

        Exclusion Criteria:

          -  Presence of intercurrent (acute) infectious disease

          -  Mental impairment (major depressive, anxiety, panic, adjustment, bipolar, psychotic,
             posttraumatic or borderline personality disorder)

          -  Presence of the following chronic diseases: diabetes mellitus, chronic obstructive
             pulmonary disease, renal failure, chronic anaemia, malignancy, rheumatoid arthritis

          -  Presence of the following cardiovascular conditions: unstable angina pectoris,
             history of myocardial infarction, uncontrolled cardiac arrhythmias causing symptoms
             or hemodynamic compromise, symptomatic (severe) aortic stenosis, uncontrolled
             symptomatic heart failure, acute myocarditis or pericarditis, left main coronary
             stenosis, moderate stenotic valvular heart disease, tachyarrhythmias or
             bradyarrhythmias, hypertrophic cardiomyopathy and other forms of outflow tract
             obstruction, high-degree atrioventricular block

          -  History of pulmonary embolus or pulmonary infarction

          -  Known aortic aneurysm

          -  Severe hypertension (&gt;170/100 mm Hg)

          -  Medication that affects cardiovascular function (beta-blocker, calcium antagonist,
             ACE-inhibitors, aldosterone-antagonists)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisanne Smans, drs</last_name>
    <phone>0031616796646</phone>
    <email>l.c.c.j.smans@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre Zelissen, dr</last_name>
    <phone>0031887550686</phone>
    <email>p.m.j.zelissen@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisanne Smans, drs</last_name>
      <phone>0031616796646</phone>
      <email>l.c.c.j.smans@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Pierre Zelissen, dr</last_name>
      <phone>0031887550686</phone>
      <email>p.m.j.zelissen@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 2, 2012</lastchanged_date>
  <firstreceived_date>August 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Smans</investigator_full_name>
    <investigator_title>drs</investigator_title>
  </responsible_party>
  <keyword>exercise capacity</keyword>
  <keyword>Addison's disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Addison Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone-17-butyrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
